Allovir Historical Balance Sheet

ALVR Stock

USD 0.45 0.01 2.17%

Trend analysis of Allovir balance sheet accounts such as Other Current Liab of 41.8 K, Total Current Liabilities of 21.2 M or Total Stockholder Equity of 158.9 M provides information on Allovir's total assets, liabilities, and equity, which is the actual value of Allovir to its prevalent stockholders. By breaking down trends over time using Allovir balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Allovir latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Allovir is a good buy for the upcoming year.

Allovir Inventory

(134,235)

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allovir. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

To learn how to invest in Allovir Stock, please use our How to Invest in Allovir guide.

About Allovir Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Allovir at a specified time, usually calculated after every quarter, six months, or one year. Allovir Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Allovir and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Allovir currently owns. An asset can also be divided into two categories, current and non-current.

Allovir Balance Sheet Chart

At this time, Allovir's Other Current Assets are relatively stable compared to the past year. As of 12/15/2024, Total Liabilities is likely to grow to about 56.5 M, while Total Current Liabilities is likely to drop slightly above 21.2 M.

Total Assets Other Current Liab Total Current Liabilities Accounts Payable Property Plant Equipment

Add Fundamental

Total Assets

Total assets refers to the total amount of Allovir assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Allovir books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Allovir balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Allovir are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents Allovir obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Allovir are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most accounts from Allovir's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Allovir current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allovir. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

To learn how to invest in Allovir Stock, please use our How to Invest in Allovir guide.At this time, Allovir's Other Current Assets are relatively stable compared to the past year. As of 12/15/2024, Total Liabilities is likely to grow to about 56.5 M, while Total Current Liabilities is likely to drop slightly above 21.2 M.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	15.3M	6.9M	44K	41.8K
Total Assets	286.6M	277.1M	190.8M	236.5M

Other Current Liab Total Assets

Allovir balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Short Long Term Debt Total	Property Plant And Equipment Net
Total Assets		0.62	0.79	0.96	0.94	-0.93	-0.87	-0.65	0.65	0.91	0.72	0.55	0.59	1.0	-0.19	0.48	-0.35	-0.92	0.95	0.83	-0.11	0.96	1.0	0.99	0.61	0.27
Other Current Liab	0.62		0.68	0.54	0.47	-0.6	-0.86	-0.17	0.6	0.8	0.9	0.31	0.93	0.58	-0.35	0.23	-0.01	-0.55	0.52	0.41	0.17	0.54	0.58	0.56	0.5	0.79
Total Current Liabilities	0.79	0.68		0.75	0.79	-0.82	-0.84	-0.82	0.97	0.92	0.76	0.11	0.68	0.77	-0.63	0.77	-0.37	-0.79	0.7	0.88	-0.07	0.75	0.77	0.72	0.89	0.39
Total Stockholder Equity	0.96	0.54	0.75		0.98	-0.8	-0.84	-0.64	0.63	0.86	0.64	0.39	0.51	0.96	-0.32	0.38	-0.59	-0.79	0.97	0.88	-0.38	1.0	0.96	0.96	0.59	0.26
Net Tangible Assets	0.94	0.47	0.79	0.98		-0.81	-0.81	-0.72	0.7	0.84	0.59	0.36	0.46	0.94	-0.34	0.5	-0.6	-0.8	0.93	0.94	-0.38	0.98	0.94	0.93	0.62	0.17
Current Deferred Revenue	-0.93	-0.6	-0.82	-0.8	-0.81		0.79	0.72	-0.7	-0.86	-0.72	-0.61	-0.57	-0.92	0.1	-0.69	0.07	1.0	-0.82	-0.77	-0.22	-0.8	-0.92	-0.9	-0.66	-0.22
Net Debt	-0.87	-0.86	-0.84	-0.84	-0.81	0.79		0.48	-0.78	-0.98	-0.77	-0.4	-0.89	-0.86	0.38	-0.37	0.33	0.76	-0.76	-0.7	0.09	-0.84	-0.86	-0.84	-0.58	-0.46
Retained Earnings	-0.65	-0.17	-0.82	-0.64	-0.72	0.72	0.48		-0.78	-0.64	-0.42	0.02	-0.17	-0.64	0.52	-0.87	0.44	0.72	-0.63	-0.87	0.16	-0.64	-0.65	-0.61	-0.85	0.03
Accounts Payable	0.65	0.6	0.97	0.63	0.7	-0.7	-0.78	-0.78		0.85	0.63	-0.01	0.68	0.63	-0.67	0.77	-0.39	-0.67	0.53	0.81	-0.1	0.63	0.64	0.58	0.83	0.28
Cash	0.91	0.8	0.92	0.86	0.84	-0.86	-0.98	-0.64	0.85		0.8	0.35	0.82	0.89	-0.44	0.52	-0.35	-0.84	0.8	0.79	-0.07	0.86	0.89	0.87	0.71	0.42
Non Current Assets Total	0.72	0.9	0.76	0.64	0.59	-0.72	-0.77	-0.42	0.63	0.8		0.23	0.7	0.67	-0.44	0.46	-0.09	-0.67	0.7	0.61	0.12	0.64	0.67	0.65	0.75	0.83
Non Currrent Assets Other	0.55	0.31	0.11	0.39	0.36	-0.61	-0.4	0.02	-0.01	0.35	0.23		0.34	0.58	0.68	0.04	0.4	-0.64	0.42	0.11	0.46	0.39	0.57	0.61	-0.18	-0.09
Other Assets	0.59	0.93	0.68	0.51	0.46	-0.57	-0.89	-0.17	0.68	0.82	0.7	0.34		0.57	-0.31	0.21	-0.03	-0.54	0.4	0.36	0.16	0.51	0.56	0.54	0.39	0.53
Cash And Short Term Investments	1.0	0.58	0.77	0.96	0.94	-0.92	-0.86	-0.64	0.63	0.89	0.67	0.58	0.57		-0.15	0.46	-0.36	-0.92	0.95	0.82	-0.12	0.96	1.0	1.0	0.56	0.22
Net Receivables	-0.19	-0.35	-0.63	-0.32	-0.34	0.1	0.38	0.52	-0.67	-0.44	-0.44	0.68	-0.31	-0.15		-0.38	0.66	0.05	-0.25	-0.54	0.51	-0.32	-0.16	-0.11	-0.74	-0.47
Common Stock Shares Outstanding	0.48	0.23	0.77	0.38	0.5	-0.69	-0.37	-0.87	0.77	0.52	0.46	0.04	0.21	0.46	-0.38		-0.05	-0.69	0.39	0.72	0.22	0.38	0.46	0.42	0.82	0.06
Non Current Liabilities Total	-0.35	-0.01	-0.37	-0.59	-0.6	0.07	0.33	0.44	-0.39	-0.35	-0.09	0.4	-0.03	-0.36	0.66	-0.05		0.05	-0.49	-0.61	0.94	-0.59	-0.36	-0.35	-0.37	-0.03
Inventory	-0.92	-0.55	-0.79	-0.79	-0.8	1.0	0.76	0.72	-0.67	-0.84	-0.67	-0.64	-0.54	-0.92	0.05	-0.69	0.05		-0.81	-0.76	-0.23	-0.79	-0.91	-0.9	-0.62	-0.15
Other Current Assets	0.95	0.52	0.7	0.97	0.93	-0.82	-0.76	-0.63	0.53	0.8	0.7	0.42	0.4	0.95	-0.25	0.39	-0.49	-0.81		0.84	-0.29	0.97	0.95	0.95	0.62	0.34
Other Stockholder Equity	0.83	0.41	0.88	0.88	0.94	-0.77	-0.7	-0.87	0.81	0.79	0.61	0.11	0.36	0.82	-0.54	0.72	-0.61	-0.76	0.84		-0.37	0.88	0.83	0.8	0.82	0.21
Total Liab	-0.11	0.17	-0.07	-0.38	-0.38	-0.22	0.09	0.16	-0.1	-0.07	0.12	0.46	0.16	-0.12	0.51	0.22	0.94	-0.23	-0.29	-0.37		-0.38	-0.13	-0.13	-0.1	0.03
Net Invested Capital	0.96	0.54	0.75	1.0	0.98	-0.8	-0.84	-0.64	0.63	0.86	0.64	0.39	0.51	0.96	-0.32	0.38	-0.59	-0.79	0.97	0.88	-0.38		0.96	0.96	0.59	0.26
Total Current Assets	1.0	0.58	0.77	0.96	0.94	-0.92	-0.86	-0.65	0.64	0.89	0.67	0.57	0.56	1.0	-0.16	0.46	-0.36	-0.91	0.95	0.83	-0.13	0.96		1.0	0.57	0.22
Net Working Capital	0.99	0.56	0.72	0.96	0.93	-0.9	-0.84	-0.61	0.58	0.87	0.65	0.61	0.54	1.0	-0.11	0.42	-0.35	-0.9	0.95	0.8	-0.13	0.96	1.0		0.52	0.2
Short Long Term Debt Total	0.61	0.5	0.89	0.59	0.62	-0.66	-0.58	-0.85	0.83	0.71	0.75	-0.18	0.39	0.56	-0.74	0.82	-0.37	-0.62	0.62	0.82	-0.1	0.59	0.57	0.52		0.48
Property Plant And Equipment Net	0.27	0.79	0.39	0.26	0.17	-0.22	-0.46	0.03	0.28	0.42	0.83	-0.09	0.53	0.22	-0.47	0.06	-0.03	-0.15	0.34	0.21	0.03	0.26	0.22	0.2	0.48

Click cells to compare fundamentals

Allovir Account Relationship Matchups

Allovir balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	139.4M	370.8M	286.6M	277.1M	190.8M	236.5M
Other Current Liab	5.4M	4.9M	15.3M	6.9M	44K	41.8K
Total Current Liabilities	9.1M	12.3M	37.9M	24.3M	28.4M	21.2M
Total Stockholder Equity	(51.5M)	353.1M	225.3M	224.5M	145.8M	158.9M
Net Tangible Assets	(51.5M)	353.1M	225.3M	224.5M	258.2M	158.6M
Net Debt	(49.3M)	(114.0M)	(171.6M)	(70.7M)	(62.7M)	(65.8M)
Retained Earnings	(55.3M)	(125.1M)	(297.1M)	(465.8M)	(656.2M)	(623.4M)
Accounts Payable	630K	963K	8.4M	3.0M	6.8M	3.6M
Cash	61.1M	122.7M	201.7M	106.1M	90.1M	110.7M
Non Current Assets Total	12.1M	9.5M	33.2M	34.0M	3.2M	3.0M
Cash And Short Term Investments	126.1M	356.3M	248.1M	233.8M	183.9M	214.6M
Net Receivables	560K	450K	50K	157K	206K	230K
Common Stock Shares Outstanding	65.1M	26.9M	62.8M	76.7M	104.1M	68.3M
Short Term Investments	65.0M	233.7M	46.5M	127.7M	93.8M	103.9M
Liabilities And Stockholders Equity	139.4M	370.8M	286.6M	277.1M	190.8M	236.5M
Non Current Liabilities Total	181.8M	5.5M	23.5M	28.2M	16.6M	15.8M
Capital Lease Obligations	11.8M	8.7M	30.1M	35.4M	27.4M	20.8M
Other Current Assets	676K	9.5M	5.2M	9.1M	3.5M	5.1M
Other Stockholder Equity	(169.4M)	478.3M	522.5M	690.8M	802.0M	416.7M
Total Liab	190.9M	17.8M	61.3M	52.6M	45.0M	56.5M
Net Invested Capital	(51.5M)	353.1M	225.3M	224.5M	145.8M	158.9M
Total Current Assets	127.3M	361.3M	253.3M	243.1M	187.6M	219.6M
Net Working Capital	118.2M	349.0M	215.5M	218.7M	159.3M	198.4M

Pair Trading with Allovir

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allovir position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allovir will appreciate offsetting losses from the drop in the long position's value.

Moving together with Allovir Stock

0.84	VALN	Valneva SE ADR	Pair Corr
0.76	ERNA	Eterna Therapeutics	Pair Corr

Moving against Allovir Stock

0.78	DYAI	Dyadic International	Pair Corr
0.67	ESPR	Esperion Therapeutics	Pair Corr
0.63	BMY	Bristol Myers Squibb	Pair Corr
0.45	GILD	Gilead Sciences Sell-off Trend	Pair Corr
0.36	DNA	Ginkgo Bioworks Holdings	Pair Corr

The ability to find closely correlated positions to Allovir could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allovir when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allovir - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allovir to buy it.

The correlation of Allovir is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allovir moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allovir moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Allovir can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Allovir Stock Analysis

When running Allovir's price analysis, check to measure Allovir's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allovir is operating at the current time. Most of Allovir's value examination focuses on studying past and present price action to predict the probability of Allovir's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allovir's price. Additionally, you may evaluate how the addition of Allovir to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Allovir Historical Balance Sheet

Allovir Inventory

(134,235)

About Allovir Balance Sheet Analysis

Allovir Balance Sheet Chart

Total Assets

Total Current Liabilities

Accounts Payable

Allovir balance sheet Correlations

Allovir Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Allovir balance sheet Accounts

Pair Trading with Allovir

Moving together with Allovir Stock

Moving against Allovir Stock

Additional Tools for Allovir Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Stockholder Equity
Inventory	+ 1.0	Current Deferred Revenue
Total Current Assets	+ 1.0	Cash And Short Term Investments
Net Working Capital	+ 1.0	Cash And Short Term Investments

Cash	- 0.98	Net Debt
Current Deferred Revenue	- 0.93	Total Assets
Inventory	- 0.92	Cash And Short Term Investments
Total Current Assets	- 0.92	Current Deferred Revenue
Cash And Short Term Investments	- 0.92	Current Deferred Revenue
Inventory	- 0.92	Total Assets